Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Diabetic Retinopathy HELP
Based on 8,831 articles published since 2008
||||

These are the 8831 published articles about Diabetic Retinopathy that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Recommendations for the use of ranibizumab in diabetic macular edema at IMSS]. 2017

Ortiz-Lerma, Roberto / González-Cervantes, Carlos Pedro / Hernández-Núñez, Fabiola / Ancona-Durán, Irene / Betesh-Rodríguez, Isaac / Méndez, Noé / Garza-Cantú, Daniel / López-Martínez, Óscar / Martínez-Ruiz, Adriana Marcela / López-Montero, Luis Miguel / Muñoz, Armando / Blancas-Ontiveros, Jorge Alberto / Fernández-Trejo, Carlos Mariano / Mayorga-Rubalcava, Juan Carlos / Flores-Góngora, Silvia Elizabeth / Gómez-Galván, Jorge Luis / Domínguez-Álvarez, Patricia Armida / Sánchez-Hernández, Erik / Cantú-Yeverinon, Homero. ·aJefatura del Servicio de Oftalmología, Hospital General "Dr. Gaudencio González Garza", Centro Médico Nacional La Raza, Ciudad de México. ·Rev Med Inst Mex Seguro Soc · Pubmed #29190870.

ABSTRACT: Diabetic macular edema can occur at any stage of diabetic retinopathy. It represents the main cause of vision loss in diabetes type I and II with a prevalence of 3-10% in diabetic patients of the Instituto Mexicano del Seguro Social (IMSS). Our aim is to elaborate treatment guidelines and provide recommendations for the use of intravitreal ranibizumab for diabetic medical edema at IMSS. Nine retina specialists and 10 ophthalmologists from IMSS high specialty medical units gathered to discuss the bibliographic evidence for the safety and efficacy of ranibizumab for this disease, in order to create consensus on its use in the institution. Intravitreal ranibizumab injection should be used on patients presenting diffuse or cystic diabetic macular edema who have strict metabolic control and visual acuity between 20/30 and 20/200 ETDRS, as well as structural features, such as inferior foveal limit of 280 μm and ischemic areas no larger than 50% of the central foveal area. Treatment regime should consist of a loading charge of three monthly injections of ranibizumab 0.5 mg, followed by monthly follow-ups and treatment as needed according to anatomic and functional criteria. This consensus decision-making process on the criteria to treat and re-treat patients with this drug will result in better health outcomes than those currently observed among patients with diabetic macular edema at IMSS.

2 Guideline Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. 2017

Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. ·Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina). ·Can J Ophthalmol · Pubmed #29074014.

ABSTRACT: -- No abstract --

3 Guideline Management della retinopatia diabetica e dell'edema maculare diabetico: linee guida "Euretina 2017". 2017

Turchetti, P / Librando, A / Angelucci, F / Carlesimo, S C / Migliorini, R. ·Istituto Nazionale per la promozione della salute delle popolazioni Migranti ed il contrasto delle malattie della Povertà. (INMP/NIHMP), Rome 00153, Italia. · Dipartimento Organi di Senso, Facoltà di Medicina e Odontoiatria, Sapienza Università di Roma, Italia. · Centro specialistico di Salute Aurelia S.R.L., Roma, Italia. ·Clin Ter · Pubmed #29044359.

ABSTRACT: Si prevede che la malattia diabetica con tutte le sue complicanze avrà un forte aumento di incidenza con un grosso impatto socioeconomico nei prossimi decenni in tutto il mondo. Pertanto ben si comprende l'importanza di individuare attraverso una fine diagnostica quanto più precocemente la comparsa dei sintomi diabetici, migliorare lo stile di vita ed impostare cure efficienti. Riportiamo la serie di raccomandazioni EURETINA 2017, dei maggiori esperti in Europa per la gestione della malattia diabetica e delle complicanze della retina. Per combattere questa "pestilenza" occorre un team medico preparato. Il trattamento laser è stato considerato sino a non molto tempo fa il Gold standard della retinopatia diabetica e dell'edema diabetico (RD e EMD). Recenti studi hanno dimostrato, invece, che si possono raggiungere risultati migliori mediante l'iniezione diretta di farmaci nella cavità vitreale. In particolare è emerso terapia di prima linea, molecole in grado di inibire il fattore di crescita endoteliale vascolare (anti VEGF) mentre non è più raccomandata la fotocoagulazione laser per il trattamento del DME. Nell'ambito delle molecole farmacologiche gli steroidi hanno mantenuto un ruolo nella gestione del DME cronicamente persistente.

4 Guideline Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. 2017

Gale, R / Scanlon, P H / Evans, M / Ghanchi, F / Yang, Y / Silvestri, G / Freeman, M / Maisey, A / Napier, J. ·The Action on DMO group, UK. · The York Hospital, York, UK. · Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. · University Hospital, Llandough, Cardiff, UK. · Bradford Teaching Hospitals, Bradford, UK. · The Royal Wolverhampton NHS Trust, Wolverhampton, UK. · Belfast Health & Social Care Trust, Belfast, UK. · Royal Hallamshire Hospital, Sheffield, UK. · Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. · Bayer, Reading, UK. ·Eye (Lond) · Pubmed #28490797.

ABSTRACT: This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients' views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.

5 Guideline The Prevention and Treatment of Retinal Complications in Diabetes. 2016

Schorr, Susanne Gabriele / Hammes, Hans-Peter / Müller, Ulrich Alfons / Abholz, Heinz-Harald / Landgraf, Rüdiger / Bertram, Bernd. ·German Agency for Quality in Medicine (ÄZQ), Berlin. ·Dtsch Arztebl Int · Pubmed #28073426.

ABSTRACT: BACKGROUND: Microvascular complications of diabetes mellitus can cause retino pathy and maculopathy, which can irreversibly damage vision and lead to blindness. The prevalence of retinopathy is 9-16% in patients with type 2 diabetes and 24-27% in patients with type 1 diabetes. 0.2-0.5% of diabetics are blind. METHODS: The National Disease Management Guideline on the prevention and treatment of retinal complications in diabetes was updated according to recommendations developed by seven scientific medical societies and organizations and by patient representatives and then approved in a formal consensus process. These recommendations are based on international guidelines and systematic reviews of the literature. RESULTS: Regular ophthalmological examinations enable the detection of retinopathy in early, better treatable stages. The control intervals should be based on the individual risk profile: 2 years for low-risk patients and 1 year for others, or even shorter depending on the severity of retinopathy. General risk factors for retinopathy include the duration of diabetes, the degree of hyperglycemia, hypertension, and diabetic nephropathy. The general, individually adapted treatment strategies are aimed at improving the risk profile. The most important specifically ophthalmological treatment recommendations are for panretinal laser coagulation in proliferative diabetic retinopathy and, in case of clinically significant diabetic macular edema with foveal involvement, for the intravitreal application of medications (mainly, vascular endothelial growth factor [VEGF] inhibitors), if an improvement of vision with this treatment is thought to be possible. CONCLUSION: Regular, risk-adapted ophthalmological examinations, with standardized documentation of the findings for communication between ophthalmologists and the patients' treating primary care physicians/diabetologists, is essential for the prevention of diabetic retinal complications, and for their optimal treatment if they are already present.

6 Guideline Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. 2016

Puliafito, Carmen A / Cousins, Scott W / Bacharach, Jason / Gonzalez, Victor H / Holekamp, Nancy M / Merrill, Pauline T / Ohr, Matthew P / Parrish, Richard K / Riemann, Christopher D. · ·Ophthalmic Surg Lasers Imaging Retina · Pubmed #27096289.

ABSTRACT: The diabetic macular edema (DME) treatment paradigm has evolved as the understanding of the disease pathology has grown. Since 2012, four pharmacotherapies have been approved by the U.S. Food and Drug Administration for the treatment of DME. First-line treatment of DME with anti-vascular endothelial growth factor [VEGF] agents has become the gold standard; however, an appreciable percentage of patients do not respond to anti-VEGF therapies. In patients who inadequately respond to anti-VEGF therapies, the underlying disease pathology may be mediated by a multitude of growth factors and inflammatory cytokines. For these patients, corticosteroids are an attractive treatment option because they not only downregulate VEGF, but also an array of cytokines. The phase 3 MEAD and FAME trials demonstrated significant visual acuity improvements associated with dexamethasone and fluocinolone acetonide, respectively, in patients with DME; however, class-specific adverse events, including increased intraocular pressure and cataract development, must be considered before use. A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology for a roundtable discussion focused on patient selection and adverse event management associated with the use of the 0.19 mg fluocinolone acetonide intravitreal implant.

7 Guideline Recommendations for the appropriate management of diabetic macular edema: Light on DME survey and consensus document by an expert panel. 2016

Bandello, Francesco / Midena, Edoardo / Menchini, Ugo / Lanzetta, Paolo. ·Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan - Italy. · Department of Neuroscience-Ophthalmology, University of Padova, Padova - Italy. · University of Florence, Clinica Oculistica AOU Careggi, Florence - Italy. · Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy. · Istituto Europeo di Microchirurgia Oculare, Udine - Italy. ·Eur J Ophthalmol · Pubmed #26776698.

ABSTRACT: PURPOSE: The Light on DME survey was designed to address several issues concerning the management of diabetic macular edema (DME) with the objective of producing practical recommendations for the appropriate treatment of this condition. METHODS: The recommendations considered aspects of DME treatment that are controversial and insufficiently supported by the evidence and were based on a consensus reached by an expert panel. Consensus was achieved by means of the Delphi method. Thirty-one Italian retinologists were asked to rate the appropriateness of a comprehensive set of scenarios typically encountered in the management of DME in clinical practice. The results of the appropriateness evaluation were analyzed by the study panel and a second assessment round was conducted for those scenarios on which no consensus was reached. RESULTS: Consensus was reached on several relevant aspects of current DME management, namely the initiation and course of treatment with anti-vascular endothelial growth factor (VEGF) therapy, assessment of the outcomes of anti-VEGF therapy based on both functional and morphologic outcomes, combination of anti-VEGF with laser therapy, and management of nonresponders to anti-VEGFs. A few issues, including the definition of DME based on novel diagnostic tools, the need for stable metabolic parameters before initiating anti-VEGF therapy, and the use of a second anti-VEFG after failure of the first anti-VEGF, proved controversial. CONCLUSIONS: A clear consensus among DME experts was reached on several relevant aspects of DME management. Based on this consensus, detailed and practical recommendations to guide ophthalmologists in the use of novel approaches to DME could be developed.

8 Guideline [Diabetic macular edema: Diagnosis and pre-treatment work-up]. 2015

Massin, P / Baillif, S / Creuzot, C / Fajnkuchen, F / Kodjikian, L / Anonymous130847. ·Cabinet d'ophtalmologie Breteuil, hôpital Lariboisière, AP-HP, université Paris Diderot, 14, avenue de Breteuil, 75007 Paris, France. Electronic address: massin.breteuil@gmail.com. · Hôpital Pasteur 2, CHU de Nice, université Nice - Sofia-Antipolis, 30, voie Romaine, 06000 Nice, France. · CHU de Dijon, université de Bourgogne, 14, rue Paul-Gaffarel, 21079 Dijon, France. · Centre d'imagerie et de laser, hôpital Avicenne, Bobigny - Paris XIII, 11, rue Antoine-Bourdelle, 75015 Paris, France. · CHU de la Croix-Rousse, hospices civils de Lyon, université Claude-Bernard - Lyon I, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France. ·J Fr Ophtalmol · Pubmed #26507784.

ABSTRACT: -- No abstract --

9 Guideline [Physician information sheet: Treatment of diabetic macular edema]. 2015

Massin, P / Baillif, S / Creuzot, C / Fajnkuchen, F / Kodjikian, L / Anonymous5350846. ·Cabinet d'ophtalmologie Breteuil, 14, avenue de Breteuil, 75007 Paris, France; Hôpital Lariboisière, université Paris Diderot, AP-HP, 2, rue Ambroise-Paré, 75010 Paris, France. Electronic address: massin.breteuil@gmail.com. · Hôpital Pasteur 2, université de Nice Sofia-Antipolis, CHU de Nice, 30, voie Romaine, 06000 Nice, France. · Université de Bourgogne, CHU de Dijon, 14, rue Paul-Gaffarel, 21079 Dijon, France. · Centre d'imagerie et de laser, hôpital Avicenne, Bobigny Paris XIII, 11, rue Antoine-Bourdelle, 75015 Paris, France. · Hospices civils de Lyon, université Claude-Bernard Lyon I, CHU de la Croix-Rousse, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France. ·J Fr Ophtalmol · Pubmed #26494496.

ABSTRACT: -- No abstract --

10 Guideline [Update on Current Care Guideline: Diabetic retinopathy]. 2015

Summanen, Paula / Kallioniemi, Vuokko / Komulainen, Jorma / Eriksson, Lars / Forsvik, Heikki / Hietala, Kustaa / Tulokas, Sirkku / Von Wendt, Gunvor / Anonymous3410838. · ·Duodecim · Pubmed #26237887.

ABSTRACT: Good treatment of diabetes decreases the risk of diabetic retinopathy. The goals of the treatment are adequate glucose balance, blood pressure and prevention of metabolic syndrome. Every patient with diabetes should regularly be screened for diabetic retinopathy. Timely and efficient treatment of retinopathy significantly decreases the risk of visual impairment.

11 Guideline TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. 2015

Freund, K Bailey / Korobelnik, Jean-François / Devenyi, Robert / Framme, Carsten / Galic, John / Herbert, Edward / Hoerauf, Hans / Lanzetta, Paolo / Michels, Stephan / Mitchell, Paul / Monés, Jordi / Regillo, Carl / Tadayoni, Ramin / Talks, James / Wolf, Sebastian. ·*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland. ·Retina · Pubmed #26076215.

ABSTRACT: PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti-vascular endothelial growth factor agents, considering factors such as criteria for extension. RESULTS: A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography-guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti-vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. CONCLUSION: It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases.

12 Guideline (12) Management of diabetes in pregnancy. 2015

Anonymous2030816. · ·Diabetes Care · Pubmed #25537713.

ABSTRACT: -- No abstract --

13 Guideline (9) Microvascular complications and foot care. 2015

Anonymous2000816. · ·Diabetes Care · Pubmed #25537710.

ABSTRACT: -- No abstract --

14 Guideline ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. 2014

Donaghue, Kim C / Wadwa, R Paul / Dimeglio, Linda A / Wong, Tien Y / Chiarelli, Francesco / Marcovecchio, M Loredana / Salem, Mona / Raza, Jamal / Hofman, Paul L / Craig, Maria E / Anonymous2260805. ·Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia; Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia. ·Pediatr Diabetes · Pubmed #25182318.

ABSTRACT: -- No abstract --

15 Guideline Diabetic retinopathy and maculopathy. 2014

Hammes, H P / Lemmen, K D / Bertram, B / Anonymous1120800. ·V. Med. Klinik, Universitätsklinikum Mannheim, Mannheim. · St. Martinus-Krankenhaus, Augenklinik, Düsseldorf. · Augenärztl. Praxis, Aachen. ·Exp Clin Endocrinol Diabetes · Pubmed #25014089.

ABSTRACT: -- No abstract --

16 Guideline Management paradigms for diabetic macular edema. 2014

Mitchell, Paul / Wong, Tien Yin / Anonymous4340776. ·Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia. · Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore. Electronic address: ophwty@nus.edu.sg. ·Am J Ophthalmol · Pubmed #24269850.

ABSTRACT: PURPOSE: To provide evidence-based recommendations for diabetic macular edema (DME) management based on updated information from publications on DME treatment modalities. DESIGN: Perspective. METHODS: A literature search for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Library, and ClinicalTrials.gov databases to identify studies from January 1, 1985 to July 31, 2013. Meta-analyses, systematic reviews, and randomized controlled trials with at least 1 year of follow-up published in the past 5 years were preferred sources. RESULTS: Although laser photocoagulation has been the standard treatment for DME for nearly 3 decades, there is increasing evidence that superior outcomes can be achieved with anti-vascular endothelial growth factor (anti-VEGF) therapy. Data providing the most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated visual improvement and favorable safety profile for up to 3 years. Average best-corrected visual acuity change from baseline ranged from 6.1-10.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for ranibizumab, compared to 1.4-5.9 ETDRS letters with laser. The proportion of patients gaining ≥ 10 or ≥ 15 letters with ranibizumab was at least 2 times higher than that of patients treated with laser. Patients were also more likely to experience visual loss with laser than with ranibizumab treatment. Ranibizumab was generally well tolerated in all studies. Studies for bevacizumab, aflibercept, and pegaptanib in DME were limited but also in favor of anti-VEGF therapy over laser. CONCLUSIONS: Anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe visual impairment caused by DME.

17 Guideline Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance. 2014

Hooper, Philip / Boucher, Marie-Carole / Colleaux, Kevin / Cruess, Alan / Greve, Mark / Lam, Wai-Ching / Shortt, Stanley / Tourville, Eric. ·Western University, London, Ont., Canada. ·Ophthalmologica · Pubmed #24246998.

ABSTRACT: Recent advances in the therapeutic options and approaches for diabetic retinopathy (DR) and diabetic macular edema (DME) have resulted in improved visual outcomes for many patients with diabetes. Yet, they have also created many clinical dilemmas for treating ophthalmologists and retina specialists, including treatment selection, initiation, frequency and duration. With this in mind, a panel of Canadian retina specialists met and discussed the current clinical evidence as well as specific situations and scenarios commonly encountered in daily practice. They also shared their experiences and therapeutic approaches. This document, containing a consensus on treatment algorithms for various clinical scenarios, is the result of their lengthy and in-depth discussions and considerations. The intent is to provide a step-by-step approach to the treatment of DR and DME. Although clinicians are encouraged to use and refer to these algorithms as a guide for various situations, they are not meant to be a replacement for sound clinical judgment.

18 Guideline Retinopathy. 2013

Anonymous5130770 / Boyd, Shelley R / Advani, Andrew / Altomare, Filiberto / Stockl, Frank. · ·Can J Diabetes · Pubmed #24070936.

ABSTRACT: -- No abstract --

19 Guideline [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: treatment of diabetic maculopathy (April 2013)]. 2013

Anonymous1040762 / Ziemssen, F / Helbig, H / Lemmen, K D / Spital, G / Bertram, B / Hillenkamp, J / Bartz-Schmidt, K U / Bornfeld, N / Bresgen, M / Eter, N / Friedrichs, W / Heimann, H / Hoerauf, H / Holz, F G / Kampik, A / Kirchhof, B / Pauleikhoff, D / Roider, J / Anonymous1050762 / Anonymous1060762 / Anonymous1070762. · ·Klin Monbl Augenheilkd · Pubmed #23794430.

ABSTRACT: -- No abstract --

20 Guideline The Royal College of Ophthalmologists' clinical guidelines for diabetic retinopathy: a summary. 2013

Ghanchi, F / Anonymous770747. · ·Eye (Lond) · Pubmed #23306724.

ABSTRACT: -- No abstract --

21 Guideline [Chronic complications of diabetes mellitus. Recommendations from the American Diabetes Association 2011. Prevention and management]. 2012

Isla Pera, Pilar / Anonymous3130739. ·Dpto. Enfermería de Salud Pública, Salud Mental y Materno Infantil, EUE, Universidad de Barcelona. pisla@ub.edu ·Rev Enferm · Pubmed #23066569.

ABSTRACT: Diabetes mellitus (DM) is one of the diseases with greater impact public health, not only because of its high prevalence, but, above all, by the consequences of the chronic complications arising from this disease. Hyperglycemia generates damage both in the field of microcirculation and the great vessels causing injury, macroangiopathies and microangiopathies. Macroangiopathies complications are generated from alterations or injury in the great vessels of the arterial to the most important, being from the clinical point of view, ischemic heart disease, disease stroke and peripheral arterial disease. Microangiopathies complications are due to alterations or injury of small vessels being the most important, from a clinical point of view, nephropathy, retinopathy and diabetic neuropathy. Macroangiopathies complications are generated from alterations or injury in the great vessels of the arterial to the most important, being from the clinical point of view, ischemic heart disease, disease stroke and peripheral arterial disease. Microangiopathies complications are due to alterations or injury of small vessels being the most important, from a clinical point of view, nephropathy, retinopathy and diabetic neuropathy.

22 Guideline Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. 2012

Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. ·Philip Hooper, London, ON. ·Can J Ophthalmol · Pubmed #22632804.

ABSTRACT: -- No abstract --

23 Guideline Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. 2012

Anonymous2420725 / Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. · ·Can J Ophthalmol · Pubmed #22560411.

ABSTRACT: -- No abstract --

24 Guideline [Intravitreal injections: AFSSAPS guide to good practice]. 2012

Bodaghi, B / Korobelnik, J F / Cochereau, I / Hajjar, J / Goebel, F / Dumarcet, N / Anonymous5700714. ·Service d'Ophtalmologie, Assistance-Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Université Pierre et Marie Curie, 47-83 bd de l'Hôpital, 75013, Paris, France. bahram.bodaghi@psl.aphp.fr ·J Fr Ophtalmol · Pubmed #22226388.

ABSTRACT: Intravitreal injections are very commonly performed in the daily practice of Ophthalmology and become a leading procedure in the management of age-related macular degeneration, diabetic retinopathy, infectious endophthalmitis or retinitis, uveitis and retinal vein occlusions. Based on the comments of a group of experts, including ophthalmologists, pharmacists and hygienists, the French Agency for the Safety of Health Products (AFSSAPS) edited a guide to good practice of intravitreal injections, revisiting those previously published in 2006. The overall experience accumulated during time is a valuable source of information to determine the most appropriate protocol. Therefore, the simplification of the procedure is reasonably proposed even though safety remains a major issue, in order to avoid complications, especially infections.

25 Guideline [Clinical practice guidelines. Diagnosis and treatment of diabetic retinopathy]. 2011

Millán-Gámez, Yuribia Karina / Wacher-Rodarte, Niels H / Bravo-Ortiz, Juan Carlos / Garrido-Gaspar, Néstor Hugo / Mendoza-Topete, Rosaura / Martínez-Ruiz, Adriana Marcela / Miller-Arrevillaga, Guillermo / Ramírez-Nájera, Alfonso. ·División de Excelencia Clínica, Coordinación de Unidades Médicas de Alta Especialidad, Distrito Federal, México. yuribia.millan@imss.gob.mx ·Rev Med Inst Mex Seguro Soc · Pubmed #22185860.

ABSTRACT: OBJECTIVE: to develop a guideline available to the staff of the second and third level of medical care, that includes recommendations based on the best available evidence about diagnosis and management of diabetic retinopathy (DR). METHODS: clinical questions were formulated and structured. A standardized sequence was established to search for practice guidelines from the clinical questions raised on diagnosis and treatment of DR. The working group searched clinical practice guidelines and found eleven on this topic. For recommendations not included in the reference guide, the search process was conducted in PubMed and Cochrane Library. The results were expressed as levels of evidence and grade of recommendation. CONCLUSIONS: in Mexico diabetic retinopathy is a main cause of blindness in the active working population. It is necessary to establish a program for detection of at-risk population that allow make early diagnosis and opportune management for reducing blindness in patients. It is equally important to be aware of the need for long-term good metabolic control, which is associated with better quality of life.

Next